Heart failure & cardiomyopathies
Clinical Phenotype and Prognosis of Real-World Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
Main finding · All-cause mortalityResult — go to the resultHazard ratio 0.55 95% CI 0.39–0.77Authors' conclusion
In this large, contemporary, real-world cohort of patients with ATTRwt-CM, predominantly in NYHA class I or II, treatment with tafamidis was consistently associated with a significantly lower risk of all-cause mortality.
Study context
- Population
- Patients with wild-type ATTR cardiomyopathy (ATTRwt-CM), 19 Italian centres, January 2017 to June 2023Propensity score (PS)-matched cohort 426 vs 426
- Participants
- 1,556 patients
- Exposure
- Tafamidis vs no disease-modifying therapy
- Tafamidisn = 965
- Untreatedn = 591reference
- Outcome
- All-cause mortality
- Follow-up
- Median 25 months (IQR 15-40)
Methodological detailspropensity-score matched, multicentre (19 Italian centres)
- Propensity-score matched
- Multicentre (19 Italian centres)
Main finding
All-cause mortality · 25 months (IQR 15-40)
Hazard ratio
0.55
95% CI 0.39–0.77
P = 0.001
Tafamidis vs Untreated
HR 0.55 (95% CI 0.39–0.77); P = 0.001
As reported in the abstract
Observational data: associations, not effects.
Original publication
Clinical Phenotype and Prognosis of Real-World Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis. Eur J Heart Fail. Published 29 November 2025. doi:10.
Summarised from the published abstract; every number is checked against it